Too soon.

For patients with diffuse large B-cell lymphoma (DLBCL), the time interval from diagnosis to treatment initiation is associated with more aggressive disease and worse survival… but not how you’d expect. This study demonstrates a shorter diagnosis to treatment interval is associated with worse patient and tumor risk factors. This likely reflects clinicians initiating therapy more urgently in patients with more aggressive disease. TBL: Patients with short diagnosis to treatment intervals are probably under participating in clinical trials, which means we could be misinterpreting the efficacy of therapies in advanced stage disease. | Maurer, J Clin Oncol 2018